The report focused on the ways in which caregivers benefit from calling helpline support, and it was published by the ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a ...

Can’t remember what you needed to buy when out for grocery shopping? Or need a minute to pinpoint the immediate neighbor’s ...

In the second of a Northern Advocate series, Denise Piper shines a light on how Alzheimer’s disease and other dementia types ...

An announcement from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available. Health Canada has authorized Leqembi (lecanemab) for treating early ...

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprote ...

However, lecanemab doesn’t stop the relentless march of Alzheimer’s disease, it just slows it down. The medication, sold under the brand name Leqembi, also comes with a hefty price tag and a risk of ...

They represent a growing number of older adults contributing to medical research not because they’re sick, but because they ...

Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...

A new study has pinpointed how the APOE4 gene variant sabotages the brain’s energy balance, blocking neurons from burning fat ...

An 80-year-old man who lost his wife to dementia last year has praised her hospice care as "like being wrapped in a cosy ...